Company intelligence / Profile preview

Therini Bio

South San Francisco, California, United Statestherinibio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Therini Bio has completed a positive Phase 1a trial of its lead candidate THN391, a high-affinity humanized monoclonal antibody targeting fibrin-driven neuroinflammation. The therapy was well-tolerated with no serious adverse events or impact on coagulation, supporting once-monthly dosing. Preclinical data also support efficacy in models of Alzheimer’s disease and diabetic macular edema. The company plans to initiate further clinical studies in these indications.

Therapeutic areas: OphthalmologyNeurology
Modalities: Monoclonal antibodies (mAbs)Bispecific antibodies (in development)
Industry: Biotech

Drug pipeline

3 assets

THN391

2 more assets in the full pipeline.

Beyond the preview

Go deeper on Therini Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Therini Bio.